pf-06463922 and Dyspnea

pf-06463922 has been researched along with Dyspnea* in 1 studies

Other Studies

1 other study(ies) available for pf-06463922 and Dyspnea

Article	Year
Lorlatinib - Induced pulmonary arterial hypertension. Lung cancer (Amsterdam, Netherlands), 2018, Volume: 120 We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib. It s the first time that a tyrosine kinase inhibitor for lung cancer is associated with pulmonary arteriel hypertension. Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Vascular Resistance; Walk Test; Withholding Treatment	2018

Article

Year

Lorlatinib - Induced pulmonary arterial hypertension.

Lung cancer (Amsterdam, Netherlands), 2018, Volume: 120

We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib. It s the first time that a tyrosine kinase inhibitor for lung cancer is associated with pulmonary arteriel hypertension.

Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Vascular Resistance; Walk Test; Withholding Treatment

2018